Proxy Perspective on Quality of Life in Prostate Cancer

描述（由申请人提供）： 在局限性前列腺癌中，对于最有利于生存的治疗替代方案没有明确的共识，每种治疗以不同的方式影响与健康相关的生活质量。在前列腺癌患者的管理中，家庭照顾者通常在与患者和医生共同决策中发挥重要作用。在癌症的更晚期阶段，家庭照顾者可能成为患者健康信息的主要来源。 护理者评估HRQL的一个关键问题是，可能会从护理者那里得出不同的观点，即，要求代理人按照他们认为患者会[代理-患者]或从代理人自己的角度[代理-代理]做出回应，并且每个观点都可以提供重要的有效信息。然而，我们知道没有研究在前列腺癌或其他比较HRQL信息提供的每一个代理的观点，目前还不清楚他们是否是系统性的不同。本研究旨在探讨在前列腺癌患者中，从代理人-代理人和代理人-患者的角度进行的HRQL评估是否存在差异，并比较患者自我评估与每个代理人观点一致的程度。将招募100名前列腺癌患者及其家庭护理者代理人，使用横断面研究设计完成EORTC QLQ C-30和EQ-5D的HRQL评估，代理人完成2项评估（从代理人-代理人和代理人-患者角度）。通过评估患者和代理人观点之间差异的一致性、统计学显著性和临床意义，研究结果对于确定代理人的观点在多大程度上影响代理人提供的信息将是重要的，并将有助于为临床决策以及标准化代理的设计和应用提供信息，在前列腺癌等疾病的临床试验中，代理受访者很重要。

DESCRIPTION (provided by applicant): In localized prostate cancer, there is no clear consensus on the treatment alternative that is most advantageous for survival, and each treatment affects health-related quality of life in different ways. In the management of prostate cancer patients, family caregivers often have a major role in shared decision making with the patient and physician. In more advanced stages of the cancer, a family caregiver may become the primary source of information on the health of patient. A crucial issue in HRQL assessment by caregivers is that different perspectives may be elicited from the caregiver, i.e., ask the proxy to respond as they think the patient would [proxy-patient] or from the proxy's own perspective [proxy-proxy], and that each viewpoint can provide important, valid information. However, we are aware of no studies in prostate cancer or otherwise that have compared the HRQL information provided by each of the proxy perspectives, and it is unclear whether they are systematically different. This study proposes to examine whether there is a difference in HRQL assessments made from the proxy-proxy and proxy-patient perspectives in prostate cancer patients, and to compare the extent to which patient self-assessment agrees with each of the proxy perspectives. One hundred prostate cancer patients and their family caregiver proxies will be recruited to complete HRQL assessments of the EORTC QLQ C-30 and EQ-5D using a cross-sectional study design, with the proxy completing 2 assessments (from the proxy-proxy and proxy-patient perspective). By evaluating concordance, statistical significance and clinical meaningfulness of differences between patient and proxy perspectives, the study results will be important in identifying the extent to which the perspective of the proxy influences the information provided by proxy, and will help to inform clinical decision-making and the design and application of standardized proxy-specific HRQL measures in clinical trials for conditions such as prostate cancer where proxy respondents are important.